429 related articles for article (PubMed ID: 21812797)
1. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
[TBL] [Abstract][Full Text] [Related]
2. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
3. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
4. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Endocr J; 2010; 57(9):777-86. PubMed ID: 20683173
[TBL] [Abstract][Full Text] [Related]
5. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
[TBL] [Abstract][Full Text] [Related]
6. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
[TBL] [Abstract][Full Text] [Related]
7. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
8. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
9. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
10. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
11. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
J Pharm Pharm Sci; 2010; 13(3):378-90. PubMed ID: 21092710
[TBL] [Abstract][Full Text] [Related]
12. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Palumbo I; Randazzo S; Cicero AF
Intern Med; 2010; 49(16):1717-25. PubMed ID: 20720348
[TBL] [Abstract][Full Text] [Related]
13. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Kuo CS; Pei D; Yao CY; Hsieh MC; Kuo SW
Int J Clin Pract; 2006 Aug; 60(8):906-10. PubMed ID: 16893433
[TBL] [Abstract][Full Text] [Related]
14. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
[TBL] [Abstract][Full Text] [Related]
15. [Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].
Zhang XJ; Wang Z; Li HH; Yu L; Gao S
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1393-6. PubMed ID: 21223671
[TBL] [Abstract][Full Text] [Related]
16. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
Chou KM; Huang BY; Fanchiang JK; Chen CH
Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
[TBL] [Abstract][Full Text] [Related]
20. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
